Access to Greenland’s minerals would give Washington more supply chain security and limit any leverage that China could to bring to bear.

The proportion of obese Indians has risen from 25 per cent in 2013 to 40 per cent in 2023, highlighting the need for ...

A dozen GLP-1 receptor agonists and coagonists demonstrated effectiveness for weight loss in adults with obesity and without ...

Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which ...

Investors have shunned high-yielding stocks as long-term bond rates rise. But some dividend stocks, particularly energy and ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

On Jan. 1, North Dakota became the first state in the country where access to drugs like Wegovy is part of the EHB package. About 55,293 of North Dakota's 784,000 residents had coverage through fully ...

The biopharma industry’s deal-a-palooza, better known as the J.P. Morgan Healthcare Conference, has kicked off in San ...

At the start of each of the last five years, the share price of Alkermes has increased. It’s the kind of steady trajectory ...

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

President-elect Donald Trump wants to buy the territory from Denmark, which says it’s not for sale. DealBook asked experts ...

Next-gen obesity biotech Metsera has filed to debut on the public markets, proposing an IPO nine months after emerging. | ...